Targeted Lipolysis Without IGF-1 Stimulation
AOD-9604 — Modified GH Fragment (hGH 176-191)
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. Unlike full-length hGH, AOD-9604 retains the lipolytic (fat-burning) activity of the parent molecule without stimulating IGF-1 production or promoting cell proliferation. It received FDA GRAS designation in 2014 and has completed Phase II and Phase III clinical trials for obesity.
AOD-9604 consists of 16 amino acids corresponding to the C-terminal fragment of hGH (positions 176–191), with a disulfide bridge between Cys182 and Cys189. This fragment contains the region responsible for hGH's lipolytic activity while lacking the N-terminal domain required for IGF-1 stimulation and cell proliferation.
AOD-9604 activates beta3-adrenergic receptors in adipose tissue, stimulating cAMP-mediated lipolysis and increasing fatty acid oxidation. Simultaneously, it suppresses acetyl-CoA carboxylase activity, reducing de novo lipogenesis and triglyceride synthesis. Unlike full-length hGH, it does not activate the JAK2/STAT5 pathway responsible for IGF-1 production.
AOD-9604 is a fragment of human growth hormone engineered to retain only the fat-burning properties of hGH while eliminating the growth-promoting and blood-sugar-disrupting effects. It received FDA GRAS status in 2014 and completed Phase III clinical trials for obesity.
AOD-9604 activates fat cells' beta3-adrenergic receptors, triggering lipolysis (fat breakdown) and blocking lipogenesis (new fat creation). It does this without raising IGF-1 or insulin, which distinguishes it from full-length growth hormone.
Most fat-loss peptides work indirectly through appetite suppression or growth hormone release. AOD-9604 acts directly on fat cells, making it a mechanistically distinct tool for metabolic research. Its FDA GRAS status and Phase III safety data give it one of the strongest regulatory profiles of any research peptide.
AOD-9604 is a GH-derived fat metabolism peptide with FDA GRAS status and Phase III clinical trial data. Its targeted lipolytic mechanism and clean safety profile make it a valuable tool for metabolic research.
Activates beta3-adrenergic receptors in adipose tissue, stimulating cAMP-mediated lipolysis and increasing fatty acid oxidation independent of IGF-1 signaling.
Suppresses acetyl-CoA carboxylase activity, reducing de novo lipogenesis and triglyceride synthesis in adipocytes.
Binds GH receptor with lower affinity than full-length hGH, activating metabolic pathways without triggering the full mitogenic or diabetogenic effects of hGH.
Metabolic Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | GH fragment (hGH 176-191) |
| Molecular Weight | 1,817.1 Da |
| Regulatory Status | FDA GRAS designation (2014); Phase III completed |
| Available Sizes | 2mg, 5mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers AOD-9604 with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase AOD-9604 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
